Patent ID: 7871769

Claim:
A method for predicting the likelihood of pathologic complete response to chemotherapy that comprises administration of both anthracycline and taxane in a human patient diagnosed with breast cancer comprising: (a) assaying the level of an CEGP1 RNA or protein in a tissue sample obtained from a breast tumor of said human patient; (b) normalizing said level against a level of at least one reference RNA or protein in said tissue sample to provide a normalized CEGP1 expression level; and (c) predicting the likelihood of pathologic complete response of the human patient to chemotherapy that comprises administration of anthracycline and taxane, wherein said prediction is based on said normalized CEGP1 expression level, wherein CEGP1 expression is negatively correlated with the likelihood of pathologic complete response to chemotherapy comprising administration of anthracycline and taxane.